IL298219A - Certain chemical compositions and methods of use thereof - Google Patents
Certain chemical compositions and methods of use thereofInfo
- Publication number
- IL298219A IL298219A IL298219A IL29821922A IL298219A IL 298219 A IL298219 A IL 298219A IL 298219 A IL298219 A IL 298219A IL 29821922 A IL29821922 A IL 29821922A IL 298219 A IL298219 A IL 298219A
- Authority
- IL
- Israel
- Prior art keywords
- 4alkyl
- compound
- nr16r17
- halo
- heterocycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063025474P | 2020-05-15 | 2020-05-15 | |
| PCT/US2021/032495 WO2021231892A1 (en) | 2020-05-15 | 2021-05-14 | Certain chemical compositions and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL298219A true IL298219A (en) | 2023-01-01 |
Family
ID=76270111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL298219A IL298219A (en) | 2020-05-15 | 2021-05-14 | Certain chemical compositions and methods of use thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11591322B2 (https=) |
| EP (1) | EP4149941B1 (https=) |
| JP (1) | JP2023526332A (https=) |
| KR (1) | KR20230051127A (https=) |
| CN (1) | CN116261561B (https=) |
| AU (1) | AU2021273072A1 (https=) |
| BR (1) | BR112022023199A2 (https=) |
| CA (1) | CA3178813A1 (https=) |
| ES (1) | ES3054109T3 (https=) |
| IL (1) | IL298219A (https=) |
| MX (1) | MX2022014356A (https=) |
| WO (1) | WO2021231892A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3054109T3 (en) | 2020-05-15 | 2026-01-29 | Algen Biotechnologies Inc | Certain chemical compositions and methods of use thereof |
| WO2023086417A1 (en) * | 2021-11-11 | 2023-05-19 | Algen Biotechnologies, Inc. | Compounds and methods of use thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4932412A (en) | 1986-12-18 | 1990-06-12 | Immunomedics, Inc. | Intraoperative and endoscopic tumor detection and therapy |
| EP1223952B1 (en) | 1999-10-07 | 2008-04-16 | Carlos Estuardo Aguilar-Cordova | Methods for treatment of solid tumors and metastasis by gene therapy |
| WO2004110350A2 (en) | 2003-05-14 | 2004-12-23 | Torreypines Therapeutics, Inc. | Compouds and uses thereof in modulating amyloid beta |
| WO2006071958A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| US8415381B2 (en) | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
| WO2012101065A2 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | Pyrimidine biaryl amine compounds and their uses |
| WO2012101063A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
| CN103339110A (zh) * | 2011-01-28 | 2013-10-02 | 诺瓦提斯公司 | 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途 |
| WO2012101066A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | Pyridine biaryl amine compounds and their uses |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| EP3126525B1 (en) | 2014-04-04 | 2020-02-19 | Memorial Sloan-Kettering Cancer Center | Method and kits for identifying of cdk9 inhibitors for the treatment of cancer |
| NZ734082A (en) | 2015-01-20 | 2019-01-25 | Boehringer Ingelheim Animal Health Usa Inc | Anthelmintic compounds, compositions and method of using thereof |
| PL3429591T3 (pl) | 2016-03-16 | 2023-07-17 | Kura Oncology, Inc. | Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania |
| EP3874045A4 (en) | 2018-10-31 | 2022-09-07 | The Regents of The University of California | Methods and kits for identifying cancer treatment targets |
| CN114025772A (zh) | 2019-04-24 | 2022-02-08 | 纪念斯隆凯特琳癌症中心 | 用于治疗ras突变体癌症的组合物和方法 |
| JP7677914B2 (ja) | 2019-06-21 | 2025-05-15 | アルゲン バイオテクノロジーズ，インク． | 標的遺伝子を特定するための方法およびシステム |
| EP4126918A4 (en) | 2020-03-31 | 2024-05-29 | The Regents of the University of California | COMPOSITIONS AND METHODS FOR IDENTIFYING HOST CELL TARGET PROTEINS FOR THE TREATMENT OF RNA VIRUS INFECTIONS |
| ES3054109T3 (en) | 2020-05-15 | 2026-01-29 | Algen Biotechnologies Inc | Certain chemical compositions and methods of use thereof |
| EP4185867A4 (en) | 2020-07-22 | 2024-08-07 | Algen Biotechnologies, Inc. | Methods and systems for determining drug effectiveness |
| WO2023086417A1 (en) | 2021-11-11 | 2023-05-19 | Algen Biotechnologies, Inc. | Compounds and methods of use thereof |
-
2021
- 2021-05-14 ES ES21730069T patent/ES3054109T3/es active Active
- 2021-05-14 KR KR1020227043684A patent/KR20230051127A/ko active Pending
- 2021-05-14 BR BR112022023199A patent/BR112022023199A2/pt unknown
- 2021-05-14 IL IL298219A patent/IL298219A/en unknown
- 2021-05-14 EP EP21730069.8A patent/EP4149941B1/en active Active
- 2021-05-14 AU AU2021273072A patent/AU2021273072A1/en active Pending
- 2021-05-14 CN CN202180059974.5A patent/CN116261561B/zh active Active
- 2021-05-14 JP JP2022569528A patent/JP2023526332A/ja active Pending
- 2021-05-14 CA CA3178813A patent/CA3178813A1/en active Pending
- 2021-05-14 WO PCT/US2021/032495 patent/WO2021231892A1/en not_active Ceased
- 2021-05-14 MX MX2022014356A patent/MX2022014356A/es unknown
-
2022
- 2022-04-28 US US17/731,943 patent/US11591322B2/en active Active
-
2023
- 2023-01-17 US US18/097,782 patent/US12264152B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN116261561A (zh) | 2023-06-13 |
| US20220289725A1 (en) | 2022-09-15 |
| US20230295135A1 (en) | 2023-09-21 |
| EP4149941A1 (en) | 2023-03-22 |
| CA3178813A1 (en) | 2021-11-18 |
| US12264152B2 (en) | 2025-04-01 |
| AU2021273072A1 (en) | 2022-12-15 |
| BR112022023199A2 (pt) | 2023-04-04 |
| KR20230051127A (ko) | 2023-04-17 |
| ES3054109T3 (en) | 2026-01-29 |
| US11591322B2 (en) | 2023-02-28 |
| CN116261561B (zh) | 2025-10-31 |
| JP2023526332A (ja) | 2023-06-21 |
| MX2022014356A (es) | 2023-03-09 |
| WO2021231892A1 (en) | 2021-11-18 |
| EP4149941B1 (en) | 2025-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11654143B2 (en) | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | |
| US10501456B2 (en) | Therapeutic agents for the treatment of HBV infection | |
| TWI714590B (zh) | 吡啶並［３，４－ｄ］嘧啶衍生物及其藥學上可被許可的鹽 | |
| US9580432B2 (en) | Fused pyrimidine compound or salt thereof | |
| IL284407B2 (en) | Opioid receptor ligands and methods for their use and preparation | |
| JP2024502433A (ja) | キナーゼ阻害剤としてのインダゾール化合物 | |
| JP2025522294A (ja) | ピリジンチェックポイントキナーゼ１（ｃｈｋ１）阻害剤及びその使用 | |
| IL261625A (en) | Inhibitors of menin-mll in bridged cycles and methods of use | |
| US20240316022A1 (en) | Indazole compounds | |
| IL261606B (en) | Inhibitors of converted menin-mll and methods of use | |
| TW202440549A (zh) | 檢查點激酶１（ｃｈｋ１）抑制劑及其用途 | |
| IL267299B (en) | Cdk4/6 inhibitor | |
| JP2024500378A (ja) | 多環状ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用 | |
| IL298219A (en) | Certain chemical compositions and methods of use thereof | |
| CN111801322A (zh) | 用于治疗中枢和周边神经系统病症的激酶抑制剂 | |
| KR20220077140A (ko) | 프로스타글란딘 e2(pge2) ep4 수용체 길항제 | |
| EA052538B1 (ru) | Производное сложного эфира пиразолзамещенного циклопентанола и его применение | |
| CN121240859A (zh) | 用于治疗健康状况的组合物和制备和使用小分子的方法 | |
| HK40009256A (en) | Novel therapeutic agents for the treatment of hbv infection | |
| HK40009256B (en) | Novel therapeutic agents for the treatment of hbv infection |